Asset profile
Pregabalin
Small molecule
Evidence outlook
Approved: Diabetic Peripheral Neuropathic Pain, Epilepsy (label: adjunctive therapy for partial-onset seizures)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
76 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 75 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Pregabalin: this drug | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | ||
| Gabapentin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | ||
| Brivaracetam | Approved | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | ||
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | ||
| Capsaicin (Qutenza) | Approved | Small molecule | TRPV1 (transient receptor potential vanilloid 1) channel | ||
| Carbamazepine | Approved | Small molecule | Sodium channels | ||
| Cenobamate (Xcopri) | Approved | Small molecule | Sodium channels + GABA-A receptors | ||
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | ||
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | ||
| Diastat | Approved | Combination | GABA-A receptor | ||
| Diazepam (Valium) | Approved | Small molecule | GABA-A receptor | ||
| Diazepam (Valtoco) | Approved | Small molecule | GABA-A receptor | ||
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | ||
| Duloxetine (Cymbalta) | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | ||
| Eslicarbazepine Acetate (Aptiom) | Approved | Small molecule | Voltage-gated sodium channel | ||
| Ethosuximide | Approved | Small molecule | T-type calcium channel |
…and 61 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(19 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
November 2026 (1)
What to watch
December 2026 (3)
What to watch
What to watch
What to watch
2027 (11)
January 2027 (1)
What to watch
March 2027 (1)
What to watch
April 2027 (1)
What to watch
June 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
October 2027 (1)
What to watch
2028 (2)
2029 (2)
September 2029 (1)
What to watch
December 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.